Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14)METex14 is an important biomarker…
Novartis has renamed the previously acquired AveXis to Novartis Gene Therapies. The change signifies the growing importance of gene therapy to building a leading, focused medicines company with advanced therapy platforms.Building on the success of Zolg…
The collaboration aims to help alleviate supply and logistical constraints in the African Union member states Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division will be sold at zero-profit to governments through Africa Me…
2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% – bringing potential reach to over 23 million patients across these initiatives Enhanced target for full carbon neu…
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran) 1 New post-hoc analysis demonstrates…
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumabSeven of ten patients discontinued eculizumab and remained on LNP023 as monotherapy, retaining hemoglobin (Hb) level…
Human health is inextricably linked to planetary health. As the impacts of climate change are being experienced around the globe, the impacts on global health are becoming more and more clear.Heat events and …
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with two or more tyrosine-kinase inhibitors (TKIs)1 Despit…
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanomaTafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2 Spartalizumab developm…
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple sclerosis (RMS)1 Approval based on two Phase III ASCLEPIOS s…
